Q#9 One reason why SARS-CoV-2 replicates efficiently in cells is because: A- SARS-COV-2 only infects

Q#9 One reason why SARS-CoV-2 replicates efficiently in cells is because:
A- SARS-COV-2 only infects cells that have a defective interferon (IFN) antiviral pathway
B- SARS-COV-2 infects only cells that do NOT express the ACE2 receptor
C- Many SARS-CoV-2 proteins can act as antagonists of the IFN response
D- SARS-CoV-2 infection does not induce IFN transcription
E- IFNs are degraded by one of the SARS-CoV-2 proteases
Q#10 A protective adaptive immune response to SARS-CoV-2 following infection or vaccination would be due to:
A- Presence of SARS-CoV-2-specific NKT memory cells
B- Presence of SARS-CoV-2-specific IgM antibodies
C- Presence high levels of systemic interferon-y
D- Presence of SARS-CoV-2-specific T and B memory cells
E- Presence of anti-inflammatory cytokines
Q#11 The SARS-CoV-2 nonstructural protein nsp1 helps protect the virus from interferon by acting at the level of
A- antibody binding
B- interferon signaling
C- protein stability
D- transcription E translation
Q#12 In lecture it was stressed that the most important reason to utilize an “intention to treat” analysis, rather than only an analysis of those who fully complied with and completed therapy, is:
A- Increased study power due to the inclusion of a larger number of subjects.
B- Adequacy of the randomization procedure can only be checked in this approach.
C- Poor outcomes among study drop-outs are included, reducing a potential source of bias.
D- Study costs are reduced.
E- Impact of full dose treatment is directly and readily observed.